点阵激光联合微乳制剂增强并维持皮肤局部递送维莫德吉
口服维莫德吉治疗基底细胞癌受全身副作用限制。本研究在猪皮肤上联合剥脱性点阵激光与维莫德吉缓释微乳制剂,评估皮肤生物分布与局部反应。结果显示激光使药物摄取较完整皮肤提高至16.6倍,浅层真皮浓度达1,409.7 μmol/L,深层真皮达62.3 μmol/L,均超过口服稳态血浆浓度(5.5-56.0 μmol/L),且血浆中未检出药物,仅见轻度局部反应。
要点
- 点阵激光联合微乳制剂可使维莫德吉在皮肤各层持续递送,峰值在5天和9天。
- 浅层真皮浓度达1,409.7 μmol/L,深层真皮达62.3 μmol/L,超过口服稳态血浆浓度。
- 激光使药物摄取较完整皮肤提高至16.6倍,血浆未检出药物,局部反应轻微。
核心结论
- 点阵激光联合维莫德吉微乳制剂可实现猪皮肤内持续高浓度递送,且皮肤耐受性良好、无血浆暴露。
研究设计与样本
- 在猪皮肤上先接受剥脱性点阵激光,再局部涂抹维莫德吉微乳制剂4小时,于4小时、2天、5天和9天评估浅层、中层和深层真皮及血浆中的药物分布(n=189次测量)和局部皮肤反应。
主要发现
- 激光暴露皮肤各层均检测到维莫德吉持续递送,峰值浓度出现在5天和9天。
- 浅层真皮最高浓度达1,409.7 μmol/L,深层真皮达62.3 μmol/L,超过既往口服维莫德吉的稳态血浆浓度(5.5-56.0 μmol/L)。
- 点阵激光使维莫德吉摄取较完整皮肤提高至16.6倍。
- 仅观察到轻度局部皮肤反应,血浆中未检测到维莫德吉。
临床怎么用
- 提示点阵激光辅助局部递送维莫德吉微乳制剂可能成为更安全的基底细胞癌治疗策略,但尚需临床验证。
局限性
- 研究在猪皮肤进行,非人类临床数据;未报告长期疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Oral administration of vismodegib for basal cell carcinoma treatment is limited by significant class-specific systemic side effects. We investigated the approach of combining ablative fractional laser-assisted drug delivery with an extended-release microemulsion formulation of vismodegib to provide efficient cutaneous delivery in vivo. The developed formulation consisted of an oil-in-water microemulsion stabilized by Tween-80. Pig skin was exposed to ablative fractional laser followed by topical application of vismodegib microemulsion for 4 hours. At 4 hours, 2 days, 5 days, and 9 days, we evaluated vismodegib biodistribution in superficial, mid, and deep dermis and plasma (n = 189 measurements) and assessed local skin reactions. Sustained topical delivery of vismodegib was detected in all depths of ablative fractional laser-exposed skin over the course of the study, with peak concentrations found at 5 days and 9 days. The highest vismodegib concentrations reached 1,409.7 μmol/liter in superficial dermis and 62.3 μmol/liter in deep dermis, exceeding steady-state plasma concentrations previously reported for oral administration of vismodegib (5.5-56.0 μmol/liter). Ablative fractional laser increased vismodegib uptake up to 16.6-fold compared with intact skin. Only mild local skin responses to vismodegib were observed, and no vismodegib was detected in plasma. We report sustained topical delivery of vismodegib in vivo at high concentrations with favorable skin tolerability, suggesting a future safer vismodegib treatment.
引用
- Olesen UH, Clergeaud G, Hendel KK, et al. Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation. J Invest Dermatol. 2020. PMID: 32135181. doi:10.1016/j.jid.2020.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。